Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Comparative prognostic performance of nine different breast cancer gene signatures in the HRneg validation cohort (n = 75)

From: A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Breast cancer gene signatures Univariate Cox regression Kaplan-Meier analysis
  Hazard ratio (95% confidence interval) Pvalue Log-rank Pvalue
HRneg/Tneg 2.38 (1.02-5.58) 0.045 0.039
STAT1 cluster [23] 2.06 (0.88-4.82) 0.095 0.088
IR-7 [25, 26] 2.17 (0.93-5.07) 0.075 0.068
IFN cluster [24] 1.62 (0.71-3.71) 0.25 0.25
ONCO-RS [19] 1.45 (0.64-3.27) 0.37 0.36
GGI [21, 31] 0.68 (0.30-1.53) 0.35 0.35
MS-14 [16] 0.84 (0.38-1.88) 0.68 0.68
NKI-70 [6] 1.33 (0.59-2.97) 0.49 0.49
CSR/wound [18] 0.68 (0.30-1.54) 0.36 0.35
  1. CSR, core serum response; GGI, genomic grade index; HRneg, hormone receptor-negative; IFN, interferon; IR-7, immune response signature with 7-gene immune response module; MS-14, Celera 14-gene metastasis score; NKI-70, 70-gene Mammaprint signature; ONCO-RS, Oncotype/Genomic Health recurrence score; STAT1, signal transducer and activator of transcription 1; Tneg, triple-negative.